Logo image of OMGA

OMEGA THERAPEUTICS INC (OMGA) Stock Fundamental Analysis

NASDAQ:OMGA - Nasdaq - US68217N1054 - Common Stock - Currency: USD

0.1426  -0.02 (-10.82%)

After market: 0.11 -0.03 (-22.86%)

Fundamental Rating

2

Overall OMGA gets a fundamental rating of 2 out of 10. We evaluated OMGA against 568 industry peers in the Biotechnology industry. OMGA has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, OMGA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OMGA has reported negative net income.
OMGA had a negative operating cash flow in the past year.
OMGA had negative earnings in each of the past 5 years.
In the past 5 years OMGA always reported negative operating cash flow.
OMGA Yearly Net Income VS EBIT VS OCF VS FCFOMGA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -47.86%, OMGA perfoms like the industry average, outperforming 48.17% of the companies in the same industry.
OMGA has a worse Return On Equity (-633.21%) than 80.98% of its industry peers.
Industry RankSector Rank
ROA -47.86%
ROE -633.21%
ROIC N/A
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMGA Yearly ROA, ROE, ROICOMGA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

OMGA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMGA Yearly Profit, Operating, Gross MarginsOMGA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

OMGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OMGA has more shares outstanding
Compared to 1 year ago, OMGA has an improved debt to assets ratio.
OMGA Yearly Shares OutstandingOMGA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
OMGA Yearly Total Debt VS Total AssetsOMGA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.95, we must say that OMGA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.95, OMGA is doing worse than 60.73% of the companies in the same industry.
A Debt/Equity ratio of 1.00 is on the high side and indicates that OMGA has dependencies on debt financing.
With a Debt to Equity ratio value of 1.00, OMGA is not doing good in the industry: 78.53% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Altman-Z -4.95
ROIC/WACCN/A
WACC9.59%
OMGA Yearly LT Debt VS Equity VS FCFOMGA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

OMGA has a Current Ratio of 1.61. This is a normal value and indicates that OMGA is financially healthy and should not expect problems in meeting its short term obligations.
OMGA has a worse Current ratio (1.61) than 80.80% of its industry peers.
OMGA has a Quick Ratio of 1.61. This is a normal value and indicates that OMGA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.61, OMGA is doing worse than 79.76% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.61
Quick Ratio 1.61
OMGA Yearly Current Assets VS Current LiabilitesOMGA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

OMGA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.06%, which is quite impressive.
Looking at the last year, OMGA shows a very strong growth in Revenue. The Revenue has grown by 184.04%.
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%

3.2 Future

The Earnings Per Share is expected to grow by 23.60% on average over the next years. This is a very strong growth
Based on estimates for the next years, OMGA will show a very strong growth in Revenue. The Revenue will grow by 150.92% on average per year.
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%

3.3 Evolution

OMGA Yearly Revenue VS EstimatesOMGA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
OMGA Yearly EPS VS EstimatesOMGA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OMGA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OMGA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMGA Price Earnings VS Forward Price EarningsOMGA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMGA Per share dataOMGA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as OMGA's earnings are expected to grow with 20.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.8%
EPS Next 3Y20.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OMGA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OMEGA THERAPEUTICS INC

NASDAQ:OMGA (2/24/2025, 8:00:02 PM)

After market: 0.11 -0.03 (-22.86%)

0.1426

-0.02 (-10.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)N/A N/A
Inst Owners81.36%
Inst Owner Change0%
Ins Owners1.4%
Ins Owner Change0%
Market Cap7.90M
Analysts82.86
Price Target13.26 (9198.74%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.6%
Min EPS beat(2)-6.31%
Max EPS beat(2)19.51%
EPS beat(4)2
Avg EPS beat(4)6.61%
Min EPS beat(4)-6.31%
Max EPS beat(4)19.51%
EPS beat(8)5
Avg EPS beat(8)8.26%
EPS beat(12)8
Avg EPS beat(12)10.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)113.47%
Min Revenue beat(2)106.48%
Max Revenue beat(2)120.46%
Revenue beat(4)4
Avg Revenue beat(4)84.74%
Min Revenue beat(4)41.91%
Max Revenue beat(4)120.46%
Revenue beat(8)8
Avg Revenue beat(8)95.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)40.54%
PT rev (3m)40.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.75%
EPS NY rev (1m)0%
EPS NY rev (3m)2.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.98
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.15
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.86%
ROE -633.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.3%
Cap/Sales 25.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.61
Quick Ratio 1.61
Altman-Z -4.95
F-Score4
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)125.73%
Cap/Depr(5y)129.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%
EBIT growth 1Y32.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.82%
EBIT Next 3Y6.19%
EBIT Next 5YN/A
FCF growth 1Y37.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.41%
OCF growth 3YN/A
OCF growth 5YN/A